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Comprehensive Review
Relieving pain using dose-extending placebos:
a scoping review
Luana Collocaa,b,c,*, Paul Enckd, David DeGraziae,f
Abstract
Placebos are often used by clinicians, usually deceptively and with little rationale or evidence of benefit, making their use ethically
problematic. In contrast with their typical current use, a provocative line of research suggests that placebos can be intentionally
exploited to extend analgesic therapeutic effects. Is it possible to extend the effects of drug treatments by interspersing placebos?
We reviewed a database of placebo studies, searching for studies that indicate that placebos given after repeated administration of
active treatments acquiremedication-like effects.We found a total of 22 studies in both animals and humans hinting of evidence that
placebos may work as a sort of dose extender of active painkillers. Wherever effective in relieving clinical pain, such placebo use
would offer several advantages. First, extending the effects of a painkiller through the use of placebos may reduce total drug intake
and side effects. Second, dose-extending placebos may decrease patient dependence. Third, using placebos along with active
medication, for part of the course of treatment, should limit dose escalation and lower costs. Provided that nondisclosure is
preauthorized in the informed consent process and that robust evidence indicates therapeutic benefit comparable to that of
standard full-dose therapeutic regimens, introducing dose-extending placebos into the clinical arsenal should be considered. This
novel prospect of placebo use has the potential to change our general thinking about painkiller treatments, the typical regimens of
painkiller applications, and the ways in which treatments are evaluated.
Keywords: Clinical outcomes, Enhancement, Expectancy, Learning, Pain, Placebo effects, Partial reinforcement,
Pharmacological conditioning, Opioids
1. Introduction
The history of medicine is replete with unintentional placebo and
nocebo effects in medical practice.22,62 Only in the 20th century,
have physicians been able to offer drugs and treatments with
specific mechanisms of action. Despite this advance, extensive
use of treatments with no proven efficacy and inadvertent use of
placebos persist in the present day.
Intentional use of placebos has been recently documented in
survey studies spanning different countries including USA,51,76,80
Canada,44,69 Germany,57,59 Switzerland,30 Denmark,48 United
Kingdom,47 Israel,63 India,75 Saudi Arabia,45 and New Zealand46
(see also Table 1). A systematic review of 22 studies from 12
different countries reported that between 17% and 80% of
clinicians interviewed have administered such placebo treatments
as sugar pills or saline injections during their careers.32 Placebos
are usually administered with little, yet unclear, rationale or
evidence of benefit, and without consent or preauthorization,
making their use scientifically, clinically, and ethically questionable.
In comparison with standard regimens of medication, dose-
extending placebos—placebos and/or subclinical doses of pain-
killers that are blended with treatments in accordance with
reinforcement learning principles—may, where effective, offer
several benefits. First, extending the effects of a medication by
interspersing placebos rather than using only medication for
a treatment of equal duration may reduce the overall intake of
painkillers. Side effects associatedwith themedicine are likely to be
reduced as well,70,71 although there is some risk of conditioned
side effects.25 Second, in cases in which the medicine is habit-
forming, dose-extending placebo use may decrease physiological
or psychological dependence on medication. Third, using dose-
extending placebos for part of the course of treatment rather than
using medication for the entire course will presumably lower costs.
Dose-extending placebos in pain medicine catalyze the body’s
capacity for endogenous pain modulatory systems.19 Any attempt
to target placebo effects through learning mechanisms—whether
or not there is active drug (that is, subclinical doses) in the
placebo—will fall under the dose-extending placebo category.
In this scoping review, we map salient concepts underlying
conditioning and placebo-induced analgesia, comprehensively
review available evidence about dose-extending placebos, and
discuss the requirements for a clinical use of dose-extending
placebos, indicating potential clinical benefits while acknowledging
possible limitations. Where ethical concerns surrounding such an
application of placebos are adequately addressed along the lines
we recommend, introducing preauthorized dose-extending place-
bos represents an innovative approach to pain management.
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1.1. The rationale beyond the prospect of
dose-extending placebos
Previous comprehensive reviews of placebo use have touched on
themes such as the possibility of harnessing placebo effects in pain
medicine, the need to focus on elements of the clinical encounter,
as well as patient–clinician relationships.14,16,52 In this study, we
focus specifically on placebos as vehicles to boost placebo effects.
While the mechanisms of learned placebo effects have been
described elsewhere,20 we selected pain- and no pain-related
studies, which pave the way to intentionally using conditioning
principles and placebos for therapeutic purposes. This timely,
innovative approach can potentially help reduce the burden of
opioid misuse in pain medicine and opioid-related addiction while
improving the satisfaction of patient with chronic pain.
Opioids are often prescribed for themanagement of any type of
pain despite the lack of high-quality evidence demonstrating
efficacy, effectiveness, and safety of long-term opioid therapy for
the management of chronic noncancer pain.36,74,79 Long-term
opioid use is associated with great risks and likely results in
greater harm than good.79 The per capita use of opioids in North
America is double that of the United Kingdom, 3 times that in the
Netherlands, and 26 times that in Japan.81,27 Opioids can induce
drug tolerance (and the need for escalating doses), hyperalgesia
(increased pain sensitivity), and addiction.81,54
Extensive research on placebo analgesia over the past several
decades has expanded knowledge of a fascinating psychoneur-
obiological phenomenon underlying endogenous pain reduc-
tion.23,52 This provocative line of research involves the use of
placebos to enhance therapeutic outcomes through learning
paradigms that produce behavioral and biological responses
mirroring those induced by active drugs.24,28,29 In particular,
studies indicate that placebos given after repeated administration
of active treatments (eg, morphine) acquire a drug-like effect (eg,
pain reduction) in both animals and humans. Moreover, it is
apparent that the effect of this modality is greater than that
obtainable through the use of placebo alone.4,21,33,34,53 Based on
research on placebo effects derived from pharmacological and
nonpharmacological conditioning, in this study, we present the first
systematic analysis of dose-extending use of placebos and factors
that need to be considered before incorporating such use into
clinical practice. Some of this research uses the term “partial
reinforcement” instead of “dose-extension” based on Pavlovian
and non-Pavlovian learning principles, but subtle differences are
unheeded here because conceptual24,28,73 and empirical6 re-
search on partial reinforcement has been previously published.
2. Search methods
We searched PubMed for articles using the search term “placebo”
to select articles dealing with the placebo effect. For the
approximately 100,000 citations retrieved in 2004, we screened
their titles and abstracts retrospectively and excluded articles
describing placebo-controlled trials of individual drugs and other
medical interventions that “only” assessed differences between
drug and placebo for evaluation of therapeutic benefits of the
therapy. We also excluded meta-analyses of placebo-controlled
trials and reviews. After exclusion of letters and editorials, we were
left with approximately 1000 articles (or approximately 1% of all
articles screened) that discussed different aspects of the placebo
response and/or placebo effects in different medical and psycho-
logical subspecialties. These were predominantly experimental
data (exploring the different mechanisms of the placebo response)
and reviews, systematic reviews, re-analyses, and meta-analyses
of randomized controlled trial data. From 2004 until 2015, this
search was repeated weekly for updates. This database currently
(December 30, 2015) contains 3023 articles addressing various
aspects of the placebo and nocebo responses in medicine and
beyond. For this review, this database was searched using the
terms “Pharmacological conditioning” (22 hits) and “conditioning”
(225 hits) (Fig. 1). All the articles were hand-searched for studies
using drug-like effects as a means to extend pharmacological
effects by the placebo effect.We also hand-searched the reference
lists of these articles to check for further citations not occurring in
our database. In this way, we identified 22 experimental studies that
fulfilled the selection criteria including pain- (10) and no pain-related
(12) studies, Figure 1. In this study, we review the identified pivotal
studies that provide the scientific rationale for placebos to be
administrated in a learning-based way so that they can act as
booster agents mimicking the action of active drugs.
2.1. Pain studies
2.1.1. Animal research on dose-extending placebos and pain
Learning from previous positive experience can create strong
memory-based analgesic responses, and similarly, previous
negative experiences can elicit nocebo effects. We designed
Table 1
Survey studies from 2003 to 2015 across different countries.
Survey study Country Number of respondents % of respondents using placebos
Tilburt et al.80 USA 679 46%-58% used placebos on a regular basis
Sherman et al.76 USA 231 45% used placebos, 8% more than 10 times in the
past year
Kermen et al.51 USA 412 56% used placebos in their clinical practice
Raz et al.69 Canada 606 20% used placebos regularly
Meissner K, et al.59 Germany 208 88% used a placebo at least once in their practice
Fa¨ssler et al.30 Switzerland 233 72% used placebos in their clinical practice
Hro´bjartsson et al.48 Denmark 503 86% used placebos at least once in the last year
Howick et al.47 United Kingdom 783 97% used placebo at least once in their career
Nitzan et al.63 Israel 89 49%-70% used placebos in their clinical practice
Shah et al.75 India 90 86% used placebos in the last year, 48%more than
10 times
Hassan et al.45 Saudi Arabia 90 68.8% used placebos in their clinical practice
Holt et al.46 New Zealand 157 34.4% used placebos 1-10 times in the last year
Placebo use included active treatments (eg, antibiotics, analgesics, sedatives, vitamins) and inert substances (eg, sugar pills, sterile lotions, saline injections). A set of survey studies across different countries indicates that
placebos have been commonly used in daily clinical practice.
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a study in which one group received a treatment perceived as
efficacious (actually, the intensity of painful stimulations was
surreptitiously decreased) and a second group received a treat-
ment perceived as ineffective (verbal suggestions with no
manipulation of the intensity of painful stimulation). When tested
for placebo analgesia, the first group reported significant reduction
of pain (49.3%), whereas the second group reported a smaller pain
reduction (9.7%).21 After 4 to 7 days, both groupswere retested for
placebo analgesia. We found that the placebo responses after the
effective procedure were significantly higher than those observed
after the ineffective treatment (29% vs 18% pain reduction).
Therefore, placebo and nocebo effects are shaped by learning
(either positive or negative previous experience), and the effect of
initial treatment exposure influences the response to subsequent
placebo responseswith obviousclinical implications.21 These sorts
of conditioned analgesic effects can be induced with pharmaco-
logical conditioning, which is effective in extending the analgesic
response to opioids and nonopioids in animals and humans.4,11,41
Similar results have been found in mice using a hot-plate test
pharmacological opioid and nonopioid conditioning.41 Conditioned
cues were paired with either the opioid agonist morphine
hydrochloride or nonopioid aspirin, and opioid and nonopioid-like
responses that were either naloxone-reversible or naloxone-
insensitive, depending on the drug used in the conditioning
procedure, were observed. Guo et al. performed a 4-day drug
conditioning experiment in female-imprinting control region mice. A
hot-plate test was used tomeasure response latencies according to
the method described by Hargraves and Hentall43 and target the
involvement of supraspinal mechanisms.55 After conditioning with
morphine, mice were treated with saline solution, exposed to the
conditioned cue cage and then tested for pain tolerance.41 Saline
solution induced enhanced pain tolerance compared with control
levels, indicating that the previous morphine conditioning was
sufficient to evoke a morphine-like analgesic effect. A pretreatment
with naloxone blocked the placebo-induced analgesia. The same
procedure described above was repeated after pharmacological
conditioning with aspirin. Interestingly, similar placebo responses
were observed except that the pretreatment with naloxone did not
block the conditioned analgesic response established by previous
conditioning with the nonopioid aspirin. Morphine conditioned
analgesic responses also affect the behavioral despair tests and
hormonal secretions inmice.42Male Sprague-Dawley rats were also
trained with 10 mg/kg morphine for 4 days to establish the placebo
analgesia model. Animals were microinjected with D-Phe-Cys-Tyr-
D-Trp-Orn-Thr-Pen-Thr-NH(2), a selective m-opioid receptor antag-
onist, naltrindole, a highly selective d-opioid receptor antagonist, or
norbinaltorphimine, a highly selective k-opioid receptor antagonist,
in the rostral anterior cingulate cortex. Only the m-opioid receptor
antagonist, but not k-opioid or d-opioid receptor antagonists,
reduced the pain threshold in conditioned placebo analgesic
responses, indicating a modulatory role of m-opioid receptors.82
Similar results have been shown in a rat model of conditioned
analgesia in an operant pain assay. Specifically, rats were
conditioned to associate a placebo manipulation with the
analgesic effect of 1-mg/kg morphine on facial thermal pain.
Conditioned (placebo) responsiveness was characterized by
3 aspects that have been reported in human research: (1) inter-
animal variability in the response, (2) suppression by the opiate
antagonist naloxone (5 mg/kg), and (3) a positive predictive
relationship between the unconditioned analgesic effect and the
conditioned (placebo) effect.64
Although negative results have been reported,58 this research
suggested that animals learn to associate contextual cues with
elevated pain tolerance, producing conditioned analgesia.
2.1.2. Human pain research
Robust analgesic responses have been documented in humans
as well. Amanzio and Benedetti performed a complex experiment
Figure 1. CONSORT flow chart.
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in which pharmacological conditioning was performed in
humans. Either morphine or ketorolac was administered for 2
consecutive days and then replaced by a placebo on the third
day. Naloxone was also given to study to what extent the
conditioned effects were antagonizable. All drugs were admin-
istered 10 minutes before inflating a sphygmomanometer cuff to
induce ischemic pain. The time interval from cuff inflation to the
last squeeze was 1 minutes, and the time interval from drug
administration to the last squeeze was the same in all subjects
(11 minutes). The pharmacological conditioning was induced by
means of either the opioid agonist morphine hydrochloride or the
nonopioid ketorolac tromethamine. Conditioning with morphine
induced robust placebo analgesic responses that were
naloxone-reversible. By contrast, ketorolac conditioning elicited
smaller placebo effects that were naloxone-insensitive.4 Opioid-
related placebo analgesic responses can be antagonized by
cholecystokinin-2 receptor agonist pentagastrin, indicating a fine
balance between cholecystokinin and opioid systems in condi-
tioned placebo analgesic effects.7,8
Different schedules of pharmacological conditioning worked in
eliciting morphine-mimicking effects, at least in the range of days
and weeks (Fig. 2). Benedetti and colleagues also performed
pharmacological conditioning with 2 morphine administrations that
were given 1 week apart. Despite the long interval, strong placebo
analgesic effects were elicited, indicating that the morphine
conditioning has long-lasting effects.11 Therefore, opioid-mediated
placebo analgesic responses can be re-evoked, and learned
analgesic effects have practical implications and applications. Using
learning principles and pharmacological agents elicits responses
that are mediated by opioidergic and nonopioid systems. Notably,
these laboratory studies designed to explore the possibility of
eliciting beneficial effects by giving placebos after pharmacological
conditioning may change therapeutic regimes.
2.2. Animal no pain-related studies
Robert Ader was one of the first scientists to introduce pivotal
concepts and a pilot clinical trial in support of the idea that
placebos may be specific therapeutics when combined with
learning principles. In the field of neuroimmunology, Ader and
Cohen performed pioneering animal and human studies to
explore the link between learned responses and therapeutic
effects. For example, they observed that merely giving a placebo
such as saccharine solution after the administration of cyclo-
phosphamide can induce immunosuppression in rats in a dose–
response manner1: rats that received 2 doses of cyclophospha-
mide during the conditioning phase had greater conditioned
immunosuppression responses than those that received one
dose of cyclophosphamide. Thus, the stronger the unconditioned
stimulus (US) the more robust the conditioned response (CR).1
Similar studies have been recently performed in Schedlowski’s
laboratory. Pacheco-Lo´pez et al. conditioned rats with 0.2%
saccharin administered just before the immunosuppressive drug
cyclosporine A, which inhibits calcineurin.65 Cyclosporine A’s
pharmacological effects were then elicited by the neutral stimulus.
The observed effects were not limited to animal behaviors but
impacted activity at the level of splenocytes such as a change in the
production of Th1-cytokine when the rats were re-exposed to the
saccharin alone. Therefore, the calcineurin activity in CD4(1)
T lymphocytes was identified as the intracellular target for inducing
placebo immunosuppression after cyclosporin A exposure,
suggesting that the use of placebos after pharmacological
conditioning triggers specific neurobiological pathways.65
2.2.1. Human research on pharmacological conditioning and
dose-extending placebos
Pharmacological conditioning has been used to study the
mechanisms underlying placebo effects in the context of motor9
and endocrine12 systems. However, there are interesting studies
in which conditioning is considered a viable strategy to harness
therapeutic conditioned effects. One of the first studies adopting
dose-extending placebos explored decrements in peripheral
leukocyte counts in 10 patients treated for multiple sclerosis with
4 intravenous cyclophosphamide treatments paired with a con-
ditioned stimulus. Eight of 10 patients showed a decreased
peripheral leukocyte count when a placebo was given after
cyclophosphamide.37
In a preclinical trial,Goebel et al. gave cyclosporineA (2.5mg/Kg)
along with a green-colored, strawberry-flavored milk drink (CS) for
healthy subjects.40 The effects of conditioned immunosuppression
were assessed by measuring interleukin 2 (IL-2) and interferon
gamma (IFN-gamma)mRNA expression, in vitro release of IL-2 and
IFN-gamma, and lymphocyte proliferation. A placebogivenwith the
flavored drink significantly suppressed immune functions in terms
of IL-2 and IFN-gamma mRNA expression, in vitro release of IL-2
and IFN-gamma, as well as lymphocyte proliferation, revealing for
the first time the mechanisms underlying conditioned immune
responses.40 More recently, a study explored the duration of such
a conditioned response, observing that the suppression of T-cell
Figure 2. Pharmacological conditioning. Morphine was given in 2 different schedules of reinforcement in the range of days (A) and weeks (B), and ischemic pain
endurance was measured (in minutes). A natural history group was also included to exclude biases and long-lasting effects of morphine. Placebo administered
after morphine elicited morphine-like effects, suggesting that a pharmacological conditioning procedure creates a learned response that can be intentionally
re-evoked. (Data from Refs. 8,11).
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function extinguished after 14 unreinforced exposures to the CS
drink. Notably, administering subtherapeutic dosages of cyclo-
sporine A (0.25 mg/Kg) along with the CS drink prevented the
extinction of the conditioned immunosuppression.3 A similar
approach was used to produce antihistamine-like effects in
patients with allergic rhinitis39 and condition behaviorally the acute
response to interferon (IFN)b-1a.38
Notably, Ader and colleagues demonstrated that placebos
given in a certain context to elicit conditioned responses can be
used with corticosteroids in patients to reduce the symptoms of
psoriasis.2 Patients were treated under a partial schedule of
pharmacologic (corticosteroid) reinforcement in which a full dose
was given 25% to 50%of the time and substituted by placebos the
other times as compared to a dose control group, inwhich patients
received the full dose 25% to 50% of the time but not placebos,
and a group receiving active corticosteroids every time. The partial
schedule of pharmacotherapeutic reinforcement with corticoste-
roid administration given one quarter or half as frequently as
currently prescribed along with dose-extending placebos was
sufficient to treat psoriasis. Indeed, the frequency of relapse under
partial reinforcement (26.7%) was lower than in the control group
(61.5%) and clinically comparable to the reduction in symptoms
induced by a full dose of corticosteroids (22.2%).2
More recently, Perlis and colleagues applied a similar thera-
peutic schedule tomedicallymanage chronic insomnia in the long
term using a partial reinforcement strategy with nightly dosing
strategies including 10 mg zolpidempill use with 50% active
medication and 50% placebos for 12 weeks. The partial
reinforcement group showed the same clinical benefit as the
other 3 groups randomized to 10 or 5 mg or intermittent 10 mg
nightly dosing.67
A recent study in children with attention deficit hyperactivity
disorder (ADHD) indicates further therapeutic potential.71 Children
were randomly assigned to 1 of 3 schedules of 8-week treatments.
Children in arm1 received a placebo pill pairedwith a 50% reduced
dose of amphetamine. The same reduction of treatment was
performed in arm 2 but without a controlled conditioned cue
(control group). Children in arm 3 received a full dose of
amphetamine treatment. Pairing a conditioned stimulus with
amphetamines produced placebo-conditioned responses that
allowed children with ADHD to be treated effectively with a lower
dose of stimulant medication. In a novel methodological twist, the
use of placebos was described to both parents and children
transparently, thus offering a model for preauthorized placebo use
in which patients are explicitly informed that placebos (eg, lactose
or talc pills) will be given to extend medication effects. Although
open label vs concealed placebos may produce different degrees
of effect, preauthorized placeboswould avoid the ethical problems
associated with deception and satisfy requirements of informed
consent.70,71 We elaborate this point in the following section.
Together, the aforementioned (and other) studies in humans
and animals suggest that pharmacological conditioning of the
immune system might impact the time course and severity of
symptoms by harnessing placebo effects.
3. Clinical requirements
As just discussed, there is significant evidence of the dose-
extending power of placebos. Although this evidence is by no
means conclusive, it motivates the following important question: If
further studies confirm these initial findings, should we consider
the possibility of introducing dose-extending placebo use into the
clinical arsenal? Might such placebo use eventually become
a component of clinical medicine? In addressing this question
against the background of the scientific rationale provided in the
previous section, we will consider several possible advantages
of using dose-extending placebos in clinical practice, several
limitations, and leading ethical considerations. If placebos
administrated in a learning-based way can act as booster
agents and mimic the action of active drugs, they might be
administered to modulate pain and other symptoms, possibly
limiting side effects and other disadvantages associated with
continued administration of active drugs. After providing
scientific background, the present section defends 3 theses
about the use of dose-extending placebos: (1) such placebo use
may be understood as a form of medical enhancement, but not
in a sense that generates ethical concerns; (2) preauthorized use
of placebos avoids the ethical difficulties associated with
deception and is consistent with professional norms governing
disclosure and informed consent; and (3) where robust
evidence indicates therapeutic benefit comparable to that of
standard treatment, we should consider the prospect of
introducing preauthorized, dose-extending placebo use into
the clinical arsenal.
By critically reviewing the studies mentioned above, the
authors agreed that further human studies are necessary to
define when the use of dose-extending placebos is effective and
in which specific medical conditions. Methodologically, the study
protocol should include 3 arms: (1) a comparator arm in which full
dose of medication is given; (2) an arm with a partial schedule of
pharmacologic reinforcement in which the full dose is given 25%
to 50% of the time and substituted by placebos at other times; (3)
a control arm in which the full dose is given 25% to 50% of the
time and no placebos are administrated. When feasible, this kind
of study design would rule out confounding changes in the
efficacy outcome measures (eg, spontaneous remission, re-
gression to the mean).
At the same time, the effective use of dose-extending placebos
might be limited by factors such as the irreversibility of a disease,
inability to adjust or optimize treatment reduction, and the
pharmacokinetic properties of the relevant agent. Safety,
optimization, and feasibility studies are needed to obtain
a meaningful assessment of dose-extending placebos in chronic
pain diseases (Box 1).
Box 1
Considerations for using dose-extending placebos to
relieve pain.
Running initial safety, feasibility, and optimization studies
Points to consider:
(1) Is the rationale for the study design scientifically and ethically sound?
(2) Is there sufficient evidence to justify the inclusion of placebos in the therapeutic
regimens (safety, feasibility, primary and secondary outcomes, and sample size)?
Performing confirmatory efficacy studies
Points to consider:
(1) Have safety, feasibility, and dose optimization been confirmed for the clinical
condition under evaluation?
(2) Have all potential biases minimized (are investigators, assessors, and participants
blinded about the treatment administration time; are treatment as usual [TAU]
control groups included; are open label placebos as effective as phase IV post-
marketing treatments)?
(3) Does the informed consent address the issue of pre-authorized use of dose-extending
placebos and post-treatment debriefing? Have health practitioners been trained to
prepare consents that are clear and understandable to any patients?
If the above criteria are met, dose-extending placebos are beneficial and ethically
acceptable are part of therapeutic regimens.
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There is a need to address specific questions. For example,
little is known about how long placebos can be used to
supplement long-term medication use and whether, and if so
when, the effectiveness of the placebo use will diminish or
disappear. Also, it is necessary to determine the following: (1)
whether conditioning with short-term acting agents (short half-
time) is more effective than conditioning with long-term acting
agents; (2) whether such a paradigm is more effective where
reactions to the drugs are consciously perceivable; and (3) which
physiological systems are more easily subject to conditioning
mechanisms. Caution is also needed in generalizing learning
effects. Conditioned compensatory responses that are opposite
to those induced by the medication can occur as a result of
tolerance, a decreased response to a drug within the course of
administrations.77 For example, Subka and Zilov demonstrated
that dogs treated with epinephrine every few days developed
tolerance, presenting tachycardic responses that decreased over
time. When epinephrine was replaced by placebo (eg, an inert
solution), an opposite bradycardic response was observed.78
Further studies are needed to understand whether predrug cues
elicit paradoxical responses because pharmacological stimula-
tions initiate adaptive responses that compensate for the primary
drug effect.
Another point to be considered is the possibility of carryover
effects from drug to drug. A recent study used pharmacological
conditioning with oxygen and aspirin in a model of high-altitude
headache.10 Both sham oxygen and sham aspirin were given
after 3 administrations of real drugs. The placebo oxygen given
after the conditioning with oxygen induced pain relief along with
a reduction in ventilation, blood alkalosis, and salivary prosta-
glandin (PG)E2. By contrast, the postconditioning placebo aspirin
induced pain relief and inhibition of the cyclooxygenase products
(eg, PGD2, PGE2, PGF2, PGI2, thromboxane (TX)A2), without
affecting either ventilation or blood alkalosis. Interestingly, a third
group received sham aspirin after conditioning with real oxygen.
None of the above physiological changes were observed,
suggesting the unlikelihood of carryover effects fromdrug to drug.
Last but not least, we expect that study participants and
patients suffering from pain vary in their response to painkillers
and therefore in their conditioned placebo analgesic effects. In
order to justify enrollment in a protocol with dose-extending
placebos, effective USs should be identified to guide health
practitioners and patients towards such a mechanistic-based,
personalized therapeutic approach.
4. Ethical considerations
4.1. Is dose-extending placebo use a form of
medical enhancement?
An additional possible source of concern regarding the prospect
of dose-extending placebos pertains to the concept of medical
enhancement. Although a great deal has been written about
placebo use in clinical practice, and placebo use in relation to
deception, it has not been previously appreciated that certain
types of placebo use might represent a form of medical
enhancement. In this study, we explain why concerns associated
with medical enhancement are easily allayed.
A substantial literature on medical enhancement has emerged
in recent decades. In most of this literature, enhancement has
been conceptualized by contrasting it with medical treat-
ment.17,50,66,72 According to this mainstream conception, while
medical treatment or therapy attempts to cure or ameliorate some
medical illness or condition, enhancement goes beyond therapy
and attempts throughmedical means to achieve improvements in
patients who are already healthy or “normal.” Some commenta-
tors have expressed concerns that enhancement lies beyond the
appropriate purview of medical practice and is therefore ethically
problematic. Importantly, this line of critique presupposes that
medical treatment and medical enhancement are mutually
exclusive, a claim we reject.
Enhancement, whethermedical or nonmedical, can be defined
as any deliberate intervention that aims to (1) improve an existing
capacity, (2) select for a desired capacity, or (3) create a new
capacity in a human being.26 This definition offers at least 2
advantages. First, unlike more traditional definitions of enhance-
ment in medical contexts, which contrast enhancement with
therapy, this definition is not tethered to any claim about what
should count as therapy and what as “beyond therapy” (a
discrimination that can be highly arbitrary and difficult in practice);
the same intervention can be both therapy and enhancement.
Second, the present conceptualization is closer to the ordinary
meaning of “enhancement,” according to which enhancement
involves some sort of improvement or growth of capacities,
whether it occurs in someone who is healthy or unhealthy.18
Dose-extending placebo use is a type of enhancement in the
present sense of the term. That is because, by activating healing
mechanisms that would otherwise be “silent,” such placebo use
either improves or creates a patient’s capacity for self-healing.
For example, a child with ADHD who benefits from a stimulant
plus a placebo that extends the stimulant’s effects will have
decreased symptoms of ADHD. An adult who suffers from
psoriasis and benefits from the use of corticosteroids in
combination with a placebo that extends their effects is better
able to reverse the symptoms of this medical condition. Even if
neither of these patients is able to “self-heal” except in the context
of dose-extending placebo use, both patients benefit from an
enhanced capacity to ameliorate the effects of their medical
condition—and very possibly with less of some of the disadvan-
tages associated with a full course of treatment, such as side
effects. The effective use of placebos in these instances lies at the
intersection of medical treatment and medical enhancement.
Precisely because this form of enhancement is also a form
a therapy, commonly advanced ethical concerns about medical
enhancement are avoided since these concerns presuppose that
enhancement is “beyond therapy.”68
4.2. Avoiding deception
From an ethical perspective, concerns arise whenever the use of
dose-extending placebos is deceptive. Historically, placebo use
has almost always involved deception, provoking ethical problems
associated with lying to or misleading patients: disrespect of the
patient’s autonomy, threats to a clinician’s integrity, and potential
damage to societal trust in the medical profession.13,15,61 For this
reason, nondeceptive (open-label) use of placebos is especially
important and especially promising from an ethical standpoint.
Contrary to the common belief that effective placebo administra-
tion requires deception, dose-extending placebos can be given
with patients’ and doctors’ agreement. A recent study along with
a survey study exploring patients’ attitudes towards placebos
suggested that placebos can be given in a nondeceptive
manner.31,49 Neither studies involved pharmacological condition-
ing (dose-extension), thus leaving somewhat unclear implications
for the approachweare advocating in this article. Nevertheless, the
use of dose-extending placebos might be clinically feasible and
can be acceptable by patients and health practitioners.
Although a benevolent use of deception to invoke a placebo
effect in clinical practice has been the subject of philosophical
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analysis35,56 and the open-label use of placebos is still under
scrutiny, we maintain that avoiding deception is ethically
paramount.60 This judgment concurs with the opinion of the
AmericanMedical Association: “Physicians may use placebos for
diagnosis or treatment only if the patient is informed of and agrees
to its use. A placebomay still be effective if the patient knows that
it will be used but they cannot identify it and do not know the
precise timing of its use.”5
A physician who believes that it would be advisable to use
a placebo to extend the effects of medication should explicitly
request preauthorization for doing so, incorporating in the
informed consent process, a statement such as the following:
“If you agree to this arrangement, then you will be given a blister
pack of painkillers and placebos and at some point during the
course of treatment youwill receive placebo rather thanmedicine,
but you won’t know when” (Fig. 3). Patients might also be
informed about the role of learning principles and how it can
shape physiological processes and therefore clinical pain out-
comes. Such a statement should be made in the context of an
appropriately full and unpressured informed consent discussion
with ample opportunity for the patient to ask questions, receive
answers, and consider alternatives; after the course of treatment,
patients should have the option of being debriefed about the
timing of placebo administration. If the patient gives informed
consent to the proposed use of placebos, and the physician goes
on to administer a placebo during the course of treatment,
concerns about deception would be eliminated.
This point merits elaboration. Neither the physician’s
communications nor his or her later behavior involves a lie
(an intentional telling of what one believes to be false so as to
make the listener believe it) or any other type of deception (a
statement or action that intentionally directs the listener to
believe what one believes to be false). The administration of the
placebo does involve nondisclosure of the fact that a placebo
is being given at that time, but the patient had earlier
consented to this arrangement; thus, the administration is
not misleading in any morally significant sense. Moreover,
because the informed consent process (we have assumed)
met appropriate ethical standards and health practitioners
who have been appropriately trained, the patient gave valid
consent to the possibility of the physician’s nondisclosure that
he or she was giving a placebo at a particular time. Thus, in our
view, such preauthorized placebo use represents an ethical
option—if there is adequate scientific confirmation that such
dose-extending placebo use is comparable in expected
benefits to standard use of the relevant medication.
5. Concluding remarks
Taken together, the studies discussed in this article suggest that
dose-extending placebo use is a distinct and significant way of
harnessing endogenous pain modulatory processes. Moreover,
as mentioned at the outset, evidence supports the assumption
that this type of placebo use has greater therapeutic value than
that of ordinary administration of placebos. With sufficient
understanding of the underlying placebo mechanisms, these
responses can be strategically elicited on the basis of a planned
sequence of medication and conditioned cues—with potential
relevance to clinical practice. These effects could be therapeu-
tically exploited in routine clinical practice by integrating placebos
in schedules of reinforcement, so that conditioned stimuli acquire
properties and characteristics of USs. Thus, dose-extending
placebo use could become part of the pharmacotherapeutic
arsenal, preserving therapeutic benefits while reducing costs,
quite possibly side effects, and perhaps dependence and
tolerance as well. Substantial use of this treatment modality over
time could offer the additional benefits of greater insight into the
human capacity for self-healing.
In sum, our proposal to consider the possibility of using dose-
extending placebos in routine clinical practice is based on
evidence that (1) placebo effects exist whenever an active
medicine is given, (2) conditioning in replacing an active medicine
with a placebo can target and boost endogenous placebo
mechanisms (beyond what a placebo alone can do) and, finally,
(3) it may be possible in this way to reduce the overall dose of
active analgesics, costs, and potentially side effects and
tolerance, all in an ethically acceptable manner. As in any
development process, confirmatory studies focusing on safety,
feasibility, and dose reduction optimization are essential before
preauthorized dose-extending placebos could potentially be
introduced in therapeutic pain management plans.
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